Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Ingavirin Forte vs Ingavirin in Healthy Volunteers
NCT07645534Phase 1Recruiting
- Sponsor
- Valenta Pharm
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Ingavirin in influenza and acute respiratory viral infection (ARVI) (4 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 6 more. Started Jul 2025; status: recruiting.
02
Drugs
Ingavirin
03
Conditions
influenzaacute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT07645534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645534.